Stockreport

Arcellx: Funded Into 2028 With Strong Clinical Data [Seeking Alpha]

Arcellx, Inc.  (ACLX) 
PDF ACLX's $576 million cash runway extends into 2028, mitigating dilution risk and supporting its transition to commercialization post-2026 launch. Anito-cel's 96% ORR, [Read more]